Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Catalio Capital Management LP

Catalio Capital Management LP cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.7% during the fourth quarter, HoldingsChannel reports. The firm owned 29,797 shares of the biopharmaceutical company’s stock after selling 5,547 shares during the quarter. Regeneron Pharmaceuticals comprises 4.3% of Catalio Capital Management LP’s holdings, making the stock its 9th largest position. Catalio Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $22,999,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. WPG Advisers LLC raised its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the period. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $29,000. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Kemnay Advisory Services Inc. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Entrust Financial LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ REGN opened at $607.93 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $503.25 and a 12-month high of $821.11. The stock’s fifty day simple moving average is $683.13 and its two-hundred day simple moving average is $734.34. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $64.27 billion, a PE ratio of 14.81, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the business posted $8.22 EPS. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Analyst Ratings Changes

Several brokerages have recently weighed in on REGN. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Royal Bank Of Canada reduced their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a report on Monday, May 18th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Finally, Canaccord Genuity Group reduced their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.